• 1
    Lader M. Benzodiazepines revisited–will we ever learn? Addiction 2011; 106: 20862109.
  • 2
    Hollister LE, Motzenbecker FP, Degan RO. Withdrawal reactions from chlordiazepoxide (‘Librium’). Psychopharmacologia 1961; 2: 6368.
  • 3
    Pariente A, Dartigues JF, Benichou J, Letenneur L, Moore N, Fourrier-Réglat A. Benzodiazepines and injurious falls in community dwelling elders. Drugs Aging 2008; 25: 6170.
  • 4
    Fang SY, Chen CY, Chang IS, Wu EC, Chang CM, Lin KM. Predictors of the incidence and discontinuation of long-term use of benzodiazepines: a population-based study. Drug Alcohol Depend 2009; 104: 140146.
  • 5
    Faccini M, Leone R, Pajusco B, Quaglio GL, Casari R, Albiero A, Donati M, Lugoboni F. Lormetazepam addiction. Data analysis from an Italian medical unit for addiction. Risk Manag Healthc Policy 2012; 5: 4348.
  • 6
    Quaglio GL, Faccini M, Vigneau CV, Casari R, Mathewson S, Licata M, Lugoboni F. Megadose bromazepam and zolpidem dependence: two case reports of treatment with flumazenil and valproate. Subst Abuse 2012; 33: 195198.
  • 7
    Quaglio GL, Lugoboni F, Fornasiero A, Lechi A, Gerra G, Mezzelani P. Dependence on zolpidem: two case reports of detoxification with flumazenil infusion. Int Clin Psychopharmacol 2005; 20: 285287.
  • 8
    Petitjean S, Ladewig D, Meier CR, Amrein R, Wiesbeck GA. Benzodiazepine prescribing to the Swiss adult population: results from a national survey of community pharmacies. Int Clin Psychopharmacol 2007; 22: 292298.
  • 9
    Ohayon MM, Lader MH. Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. J Clin Psychiatry 2002; 63: 817825.
  • 10
    De las Cuevas C, Sanz EJ, de la Fuente JA, Padilla J, Berenguer JC. The Severity of Dependence Scale (SDS) as screening test for benzodiazepine dependence: SDS validation study. Addiction 2000; 95: 245250.
    Direct Link:
  • 11
    Hood S, O'Neil G, Hulse G. The role of flumazenil in the treatment of benzodiazepine dependence: physiological and psychological profiles. J Psychopharmacol 2009; 23: 401409.
  • 12
    Liebrenz M, Boesch L, Stohler R, Caflisch C. Agonist substitution – a treatment for high-dose benzodiazepine-dependent patients? Addiction 2010; 105: 18701874.
  • 13
    Quaglio GL, Pattaro C, Gerra G, Mathewson S, Verbanck P, Des Jarlais DC, Lugoboni F. High dose benzodiazepine dependence: description of 29 patients treated with flumazenil infusion and stabilised with clonazepam. Psychiatry Res 2012; 198: 457462.
  • 14
    Gerra G, Zaimovich A, Giusti F, Moi G, Brewer C. 2002). Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo-controlled study. Addict Biol 2002; 7: 385395.
  • 15
    Lugoboni F, Leone R. What is stopping us from using flumazenil? Addiction 2012; 107: 1359.
  • 16
    Hulse G, O'Neill G, Morris N, Bennett K, Norman A, Hood S. Withdrawal and psychological sequelae, and patient satisfaction associated with subcutaneous flumazenil infusion for the management of benzodiazepine withdrawal – a case series. J Psychopharmacol 2013; 27: 222227.
  • 17
    Albiero A, Brigo F, Faccini M, Casari R, Quaglio GL, Storti M, Fiaschi A, Bongiovanni LG, Lugoboni F. Focal nonconvulsive seizures during detoxification for benzodiazepine abuse. Epilepsy Behav 2012; 23: 168170.